Paloma Partners’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Paloma Partners’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-79,565	Closed	-$307K	–	2157
2018 Q2	$307K	Buy	79,565 +62,971	+379%	+$418K	0.01%	1268
2018 Q1	$105K	Sell	16,594 -11,566	-41%	-$95.7K	﹤0.01%	1841
2017 Q4	$227K	Buy	+28,160	New	+$263K	﹤0.01%	1678
2014 Q4	–	Sell	-2,392	Closed	-$166K	–	1498
2014 Q3	$166K	Buy	+2,392	New	+$128K	0.01%	865
2013 Q3	–	Sell	-1,665	Closed	-$88K	–	1332
2013 Q2	$88K	Buy	+1,665	New	+$73K	﹤0.01%	1074

Other funds holding MACK

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Paloma Partners's MACK Position: Q3 2018 in Review

Paloma Partners sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2018, closing a stake of 79,565 shares — an estimated $307K sold.

Paloma Partners first reported a position in MACK in Q2 2013 and held it in 5 quarters. The position peaked at $307K in Q2 2018. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2018.

Paloma Partners reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Paloma Partners sold 79,565 Merrimack Pharmaceuticals, Inc. shares in Q3 2018, an estimated $307K.
Paloma Partners first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 5 quarters.
Paloma Partners's Merrimack Pharmaceuticals, Inc. position peaked at $307K in Q2 2018.
63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2018.

Based on Paloma Partners's 13F filing for Q3 2018, filed 14 Nov 2018.